Lisa M Bailey - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Lisa M Bailey

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Molecular Cancer Therapeutics|May 20, 2016

Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis XenograftXinxin Song, Se-Hoon Hong, William T Kwon, et al.

Journal of Molecular Medicine (Berlin, Germany)|September 7, 2011

A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiencyLungisa Mayende, Rachel D Swift, Lisa M Bailey, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumorsKotaro Sasaki, Angela D Pardee, Yanyan Qu, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Molecular Cancer Therapeutics|May 20, 2016

Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis XenograftXinxin Song, Se-Hoon Hong, William T Kwon, et al.

Journal of Molecular Medicine (Berlin, Germany)|September 7, 2011

A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiencyLungisa Mayende, Rachel D Swift, Lisa M Bailey, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumorsKotaro Sasaki, Angela D Pardee, Yanyan Qu, et al.

Pageof 2